Pacific Edge says it isn't out of the game in the US, it's at the midway point of the match

Pacific Edge says it isn't out of the game in the US, it's at the midway point of the match
To be or not to be in Medicare? That's the question facing NZX-listed Pacific Edge. (Image: Pacific Edge)
Rebecca Stevenson
The head of listed cancer diagnostics company Pacific Edge says its singular focus on the United States market is not a single point of failure. Pacific Edge’s share price has taken a hammering after it announced earlier this year it could lose access to the US Medicare system after Novitas – which administers Medicare – determined the Dunedin-based company’s products did not meet new thresholds for coverage under the US Social Security Act. On Monday, its shares were again buffeted by negative news when the US...

More Markets

NZ sharemarket lifts off after Auckland Airport numbers
Markets Market close

NZ sharemarket lifts off after Auckland Airport numbers

The S&P/NZX 50 Index closed at 12,943.57, gaining 59.19 points or 0.46%.

Graham Skellern 15 Jan 2025
Auckland Airport numbers bounce back
Markets

Auckland Airport numbers bounce back

Numbers highest since the pandemic hit five years ago.

Staff reporters 15 Jan 2025
NZD outlook: 2025 more about surviving
Markets

NZD outlook: 2025 more about surviving

The kiwi shed more than 11% in 2024, and we already see more downsides. 

Rebecca Howard 15 Jan 2025
Rate decision odds are tight, NZD set for a wild ride
Markets Best of BusinessDesk

Rate decision odds are tight, NZD set for a wild ride

It did turn out to be an understatement. 

Rebecca Howard 15 Jan 2025